| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Brenner Robert | Chief Medical Officer | C/O VERA THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE | /s/ Joseph R. Young, Attorney-in-Fact | 25 Feb 2026 | 0002006910 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VERA | Class A Common Stock | Sale | $90,307 | -2,151 | -4.1% | $41.98 | 50,947 | 23 Feb 2026 | Direct | F1, F2, F3 |
| Id | Content |
|---|---|
| F1 | The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. |
| F2 | Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. |
| F3 | The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. |